Patents Issued in February 9, 2021
-
Patent number: 10913772Abstract: Provided is a peptide for preventing or treating inflammatory diseases and a use thereof. According to a novel dimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances and will be expected to be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.Type: GrantFiled: January 3, 2019Date of Patent: February 9, 2021Assignee: KINE SCIENCES CO., LTD.Inventors: Dae Ho Cho, Kyung Eun Kim, Sun Young Park, Youn Kyung Houh
-
Patent number: 10913773Abstract: Anticachexin C1 inhibits the TNF?-TNF? receptor interaction. In this work, analogs of anticachexin C1 are disclosed. The resulting bicyclic peptides inhibit TNF? TNF?-induced cell death, NF-?B activation, and c-Jun N-terminal kinase (JNK) signaling in cultured mammalian cells. Methods of using the bicyclic peptide anticachexin C1 analogs to treat cancer, inflammatory disorders and immune disorders are also described.Type: GrantFiled: November 22, 2017Date of Patent: February 9, 2021Assignee: Ohio State Innovation FoundationInventor: Dehua Pei
-
Patent number: 10913774Abstract: Cyclic peptides represented by (Formula 1) selectively bind the oncoprotein K-Ras G12D in vitro and in cellulo, where Z1 and Z2 are each L-propargylglycine (Pm), azidoornithine (OrnN3), or L-azidolysine (Az4), and V1-V2-V3-V4-V5 is an amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20.Type: GrantFiled: July 10, 2018Date of Patent: February 9, 2021Assignee: California Institute of TechnologyInventors: Ryan K. Henning, Ashwin N. Ram, Samir Das, Arundhati Nag, James R. Heath
-
Patent number: 10913775Abstract: This document provides methods and materials related to the use of nucleic acid coding for viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, methods for making engineered viral nucleic acid, methods for identifying infectious nucleic acid for treating cancer, methods and materials for controlling virus-mediated cell lysis, and methods and materials for assessing the control of virus-mediated cell lysis are provided.Type: GrantFiled: March 27, 2018Date of Patent: February 9, 2021Assignee: Mayo Foundation for Medical Education and ResearchInventors: Stephen James Russell, Elizabeth J. Kelly, Elizabeth M. Hadac
-
Patent number: 10913776Abstract: Disclosed is an immunogen comprising a fusion protein, wherein the fusion protein comprises a Zika virus (ZIKV) envelope protein, optionally a signal peptide, and a multimerization domain. The signal peptide is a premembrane (prM) signal peptide, an IgG signal peptide, or a human secretory signal peptide hidden Markov model, and the multimerization domain is an immunoglobulin Fc domain, a T4 fibritin foldon trimerization domain, or a human collagen XV trimerization domain. Nucleic acids, vectors, and microneedle arrays including these compositions are disclosed. Methods of producing an immune response to ZIKV are also disclosed.Type: GrantFiled: September 29, 2017Date of Patent: February 9, 2021Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Andrea A. Gambotto, Eun Kim, Geza Erdos, Louis D. Falo, Jr.
-
Patent number: 10913777Abstract: The present disclosure is related to a BMC fusion protein that is capable of in vitro assembly, comprising a constituent BMC shell protein subunit and a sterically hindering protein domain that is cleavable. The BMC fusion protein is capable of in vitro assembly triggered by removal of the fused sterically hindering domain. The present disclosure is also related to a means to produce BMC shells in vitro, triggered by removal of a fused sterically hindering domain from one or more constituent BMC shell protein subunits. The BMC fusion protein enables encapsulation of broad classes of materials and biophysical studies of shell assembly, encapsulation, and permeability that would otherwise be unavailable from BMCs assembled in vivo.Type: GrantFiled: May 21, 2018Date of Patent: February 9, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Andrew Ronald Hagen, Cheryl A. Kerfeld, Markus Sutter
-
Patent number: 10913778Abstract: The disclosure provides a fusion polypeptide specific for both CD137 and GPC3, which fusion polypeptide can be useful for directing CD137 clustering and activation to GPC3-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.Type: GrantFiled: May 18, 2016Date of Patent: February 9, 2021Assignee: Pieris Pharmaceuticals GmbHInventors: Marlon Hinner, Rachida Siham Bel Aiba, Christine Rothe, Shane Olwill, Corinna Schlosser
-
Patent number: 10913779Abstract: Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing fusion polypeptides. These fusion polypeptides contain two or more domains: (i) aptamer sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous and viral lesions, (ii) immunomodulators, such as cytokines, and optionally (iii) at least one linker joining the two domains or at the terminus of the polypeptide. In some cases, the linker is a rigid linker, e.g., a rigid helical linker. Also provided herein are methods of treating cancer and/or infectious diseases using the new fusion polypeptides.Type: GrantFiled: January 25, 2018Date of Patent: February 9, 2021Assignee: Counterpoint Biomedica LLCInventors: Frederick L. Hall, Erlinda M. Gordon
-
Patent number: 10913780Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) including but not limited to conjugates comprising FK-506 and ascomycin. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.Type: GrantFiled: March 23, 2017Date of Patent: February 9, 2021Assignee: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Joseph A. Fuselier, David H. Coy
-
Patent number: 10913781Abstract: Disclosed here is the rational design and use of potent and specific GPCR antagonist pepducins based on GPCR regions such as the third intracellular loop and adjacent regions.Type: GrantFiled: April 9, 2012Date of Patent: February 9, 2021Assignee: Tufts Medical Center, Inc.Inventors: Athan Kuliopulos, Lidija Covic
-
Patent number: 10913782Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.Type: GrantFiled: April 12, 2016Date of Patent: February 9, 2021Assignee: Biogen MA Inc.Inventors: Hq Han, Xiaolan Zhou
-
Patent number: 10913783Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.Type: GrantFiled: April 14, 2017Date of Patent: February 9, 2021Assignee: H. LUNDBECK A/SInventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Patent number: 10913784Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.Type: GrantFiled: September 13, 2019Date of Patent: February 9, 2021Assignee: BIOAGE LABS, INC.Inventors: Robert Hughes, William Strohl
-
Patent number: 10913785Abstract: Disclosed is a T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E6, E629-38. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.Type: GrantFiled: May 10, 2019Date of Patent: February 9, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Christian S. Hinrichs, Steven A. Rosenberg
-
Patent number: 10913786Abstract: The present disclosure relates to isolated polypeptides that inhibit Wnt signaling, pharmaceutical compositions comprising the isolated polypeptides, and methods of use thereof. Nucleic acids, cells, and methods of production related to the isolated polypeptides and compositions are also disclosed.Type: GrantFiled: March 21, 2017Date of Patent: February 9, 2021Assignee: Children's Medical Center CorporationInventors: Min Dong, Liang Tao
-
Patent number: 10913787Abstract: Provided herein are polypeptides that bind to Musk compounds. Also provided are nucleic acid sequences that encode for the polypeptides. Further provided herein is a method for identifying a compound that activates, mimics, blocks, inhibits, modulates, and/or enhances the activity of an olfactory receptor that is activated by a polycyclic Musk or a nitro Musk wherein the receptor is a polypeptide having an amino acid sequence that is at least 75% identical to Olfr96 or OR11A1, wherein the method includes a) contacting the receptor, or a chimera or fragment thereof with a compound and b) determining whether the compound has an effect on the activity of the receptor.Type: GrantFiled: June 9, 2016Date of Patent: February 9, 2021Assignee: Firmenich SAInventors: Patrick Pfister, Matthew Rogers
-
Patent number: 10913788Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dry eye, the pharmaceutical composition including, as an active component, a novel peptide is disclosed, wherein it is confirmed that the peptide has effects on improving tear production and corneal surface smoothness for dry eyes induced by desiccation stress and suppressing detachment of corneal epithelial cells, reduction in conjunctival goblet cells, and generation of inflammatory factors, thereby applying a composition including the peptide as an active component to the pharmaceutical composition for preventing or treating dry eye.Type: GrantFiled: November 24, 2015Date of Patent: February 9, 2021Assignee: EYEBIO KOREAInventors: Jae Wook Yang, Hye Sook Lee, Chae Eun Kim, Kun Moo Lee
-
Patent number: 10913789Abstract: A chimeric protein having deubiquitinase activity, methods of identifying anti-deubiquitinase compounds using chimeric proteins, and kits comprising chimeric proteins are described herein. In one aspect, a chimeric protein comprises a mammalian deubiquitinase catalytic domain, a linker domain, and a non-human deubiquitinase proteasome binding domain. In another aspect, a method of identifying a compound having deubiquitinase inhibition activity comprises a) providing an assay for identifying a compound having deubiquitinase inhibition activity, wherein the assay comprises one or more biological cells comprising a chimeric protein comprising a mammalian deubiquitinase catalytic domain, a linker domain, and a non-human deubiquitinase proteasome binding domain; b) screening the assay with at least one compound; and c) identifying a compound having deubiquitinase inhibition activity based on survival of the biological cell.Type: GrantFiled: April 29, 2020Date of Patent: February 9, 2021Assignee: The Florida State University Research Foundation, Inc.Inventor: Robert J. Tomko, Jr.
-
Patent number: 10913790Abstract: A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), Mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.Type: GrantFiled: August 13, 2019Date of Patent: February 9, 2021Assignee: The Regents of the University of Colorado, a body corporateInventor: Leland Shapiro
-
Patent number: 10913791Abstract: Anti-SpA murine, chimeric and humanized monoclonal antibodies, and variant antibodies having a heavy chain with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections.Type: GrantFiled: October 28, 2019Date of Patent: February 9, 2021Inventor: Nicholas B. Lydon
-
Patent number: 10913792Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.Type: GrantFiled: January 26, 2018Date of Patent: February 9, 2021Assignee: Morphosys AGInventors: Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
-
Patent number: 10913793Abstract: Antibodies which bind and neutralize human IL-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.Type: GrantFiled: October 25, 2019Date of Patent: February 9, 2021Assignee: Eli Lilly and CompanyInventors: Robert Jan Benschop, Julian Davies, Angela Jeannine Okragly, Chetankumar Natvarlal Patel, Stephanie Marie Truhlar
-
Patent number: 10913794Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.Type: GrantFiled: November 17, 2017Date of Patent: February 9, 2021Assignee: VITAERIS INC.Inventors: Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
-
Patent number: 10913795Abstract: Compositions and methods for minimizing antibody disulfide bond reduction are described. In one aspect, a composition is provided for culturing mammalian host cells to express an antibody including an anti-reduction agent that minimizes reduction of a disulfide bond in the antibody or fragment thereof. In some other aspects, methods for minimizing disulfide bond reduction; increasing production of an antibody or fragment thereof with intact native disulfide bonds; increasing a ratio of non-reduced to reduced antibody or fragment thereof; producing a therapeutic antibody or fragment thereof by adding a sufficient amount of an anti-reduction agent to a cell culture media, pre-harvest cell culture fluid, or harvest cell culture fluid are described. In another aspect, minimizing disulfide bond reduction in an antibody or fragment thereof culturing the host cell in a concentration of at least about 20% O2 is described.Type: GrantFiled: May 16, 2018Date of Patent: February 9, 2021Assignee: ImmunoGen, Inc.Inventor: Sven Loebrich
-
Patent number: 10913796Abstract: The presently disclosed subject matter provides fully human antibodies or antigen-binding fragments thereof that bind to FcRL5 and methods of using the same.Type: GrantFiled: June 4, 2018Date of Patent: February 9, 2021Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
-
Patent number: 10913797Abstract: Anti-PD-1 antibodies and uses thereof in treating diseases associated with the PD-1 signaling, such as cancer, infectious diseases such as viral infection or immune related diseases.Type: GrantFiled: November 17, 2016Date of Patent: February 9, 2021Assignee: Lyvgen Biopharma Holdings LimitedInventors: Jieyi Wang, Liqun Dong, Yaolin Wang
-
Patent number: 10913798Abstract: Provided herein are, inter alia, methods of identifying agents that are capable inhibiting the binding (e.g., coupling) between a ROR1 protein and a ROR2 protein. By interfering with ROR1-ROR2 coupling (binding) the agents identified using the methods provided herein inhibit non-canonical Wnt5a signaling. Thus, the agents identified by the methods provided herein may, inter alia, be useful for cancer diagnosis and therapy.Type: GrantFiled: April 25, 2016Date of Patent: February 9, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Thomas J. Kipps, Jian Yu
-
Patent number: 10913799Abstract: Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.Type: GrantFiled: October 20, 2017Date of Patent: February 9, 2021Assignee: Eli Lilly and CompanyInventors: Andrew Ihor Korytko, Victor H Obungu
-
Patent number: 10913800Abstract: Disclosed herein, in certain embodiments, are anti-transferrin receptor antibodies, anti-transferrin receptor antibody conjugates, and pharmaceutical compositions which comprise the anti-transferrin receptor antibodies or conjugates. In some embodiments, also disclosed herein are methods of delivering a payload utilizing an anti-transferrin receptor antibody described herein, and methods of treatment with use of an anti-transferrin receptor antibody described herein.Type: GrantFiled: June 9, 2020Date of Patent: February 9, 2021Assignee: AVIDITY BIOSCIENCES, INC.Inventors: Beatrice Diana Darimont, Venkata Ramana Doppalapudi, Rachel Johns
-
Patent number: 10913801Abstract: The present invention relates to antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.Type: GrantFiled: January 23, 2017Date of Patent: February 9, 2021Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Hemanta Baruah, Cheng Chen, Xiaolin Liu, Andy Tsun, De-Chao Michael Yu
-
Patent number: 10913802Abstract: Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.Type: GrantFiled: July 21, 2016Date of Patent: February 9, 2021Assignee: Dyax Corp.Inventors: Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
-
Patent number: 10913803Abstract: The present invention is directed to novel heterodimeric antibodies.Type: GrantFiled: April 4, 2018Date of Patent: February 9, 2021Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
-
Patent number: 10913804Abstract: The present invention relates to a process for separating natural rubber deriving from non-Hevea type plants, in the form of solid crumbs, from solutions in an organic solvent system including it, where said organic solvent system may comprise at least one nonpolar organic solvent, or a mixture of at least one nonpolar organic solvent and at least one polar organic solvent, and the concomitant removal of said organic solvent system from said rubber, where the aforementioned process comprises subjecting said solution to a stripping stage by means of water vapor, in presence of a dispersing system, separating the aforementioned crumbs of natural rubber from the liquid phase, obtained through the stripping stage, and subjecting said crumbs to drying.Type: GrantFiled: December 13, 2016Date of Patent: February 9, 2021Assignee: Versalis S.P.A.Inventors: Tommaso Prando, Giovanni Regattieri, Maria Parisi, Dario Ghidoni
-
Patent number: 10913805Abstract: The present invention relates to a modifier useful for the modification of a conjugated diene-based polymer, having excellent affinity with a filler, and capable of improving the compounding properties of a conjugated diene-based polymer, a method for preparing the same, a modified conjugated diene-based polymer including the modifier, and a method for preparing the polymer.Type: GrantFiled: July 13, 2018Date of Patent: February 9, 2021Inventors: Min Sik Mun, Da Won Chai, Ho Young Lee
-
Patent number: 10913806Abstract: A (meth)acrylic conductive material which contains a (meth)acrylic elastomer and a conductive agent, and which is characterized in that: the (meth)acrylic elastomer is obtained by polymerizing a monomer component containing a (meth)acrylic monomer represented by formula (I) (wherein R1 represents a hydrogen atom or a methyl group; and R2 represents an alkyl group having 1-10 carbon atoms, which may have a hydroxyl group or a halogen atom, or an alkoxyalkyl group having 2-12 carbon atoms, which may have a hydroxyl group); and the (meth)acrylic elastomer has a weight average molecular weight of 1,200,000 to 10,000,000 and a molecular weight distribution (weight average molecular weight/number average molecular weight) of 1-6.Type: GrantFiled: July 19, 2017Date of Patent: February 9, 2021Assignee: OSAKA ORGANIC CHEMICAL INDUSTRY LTD.Inventors: Kanami Fujii, Yuya Tomimori, Mitsuhiro Kouda
-
Patent number: 10913807Abstract: Crosslinkable polymeric materials, crosslinked polymeric materials, articles containing the crosslinkable polymeric materials or crosslinked polymeric materials, and methods of making the articles and various compositions are provided. More particularly, the crosslinkable composition contains a) a first polymeric material, which has terminal dithiocarbamate or dithiocarbonate groups, b) a crosslinking composition containing a chlorinated triazine crosslinking agent and/or a crosslinking monomer having two or more ethylenically unsaturated groups, and c) a thixotropic agent containing metal oxide particles. The crosslinkable composition may be printable or dispensed. In some embodiments, the crosslinked composition is a pressure-sensitive adhesive.Type: GrantFiled: December 14, 2018Date of Patent: February 9, 2021Assignee: 3M Innovative Properties CompanyInventors: Serkan Yurt, Stephen B. Roscoe, George W. Griesgraber, Babu N. Gaddam, Kevin M. Lewandowski, Bryan T. Whiting, Haeen Sykora, Aaron T. Hedegaard, Jayshree Seth, Janet A. Venne
-
Patent number: 10913808Abstract: The present disclosure provides a supported catalyst system and process for use thereof. In particular, the catalyst system includes an unbridged metallocene compound, an additional unbridged metallocene compound having a structure different than the first unbridged metallocene compound, a support material and an activator. The catalyst system may be used for preparing polyolefins.Type: GrantFiled: June 22, 2018Date of Patent: February 9, 2021Assignee: ExxonMobil Chemical Patents Inc.Inventors: Matthew W. Holtcamp, Laughlin G. McCullough, Matthew S. Bedoya, David F. Sanders, Charles J. Harlan, Ching-Tai Lue, Subramaniam Kuppuswamy
-
Patent number: 10913809Abstract: A cross-linked polymeric material is formed by polymerizing a polyethylene glycol di(meth)acrylate and a sulfonate salt containing a double bond that facilitates covalent bonding of the sulfonate salt to the polyethylene glycol di(meth)acrylate. In the polymeric material, cations from the salt are optionally replaced with metal ions selected from sodium, lithium, aluminum, magnesium, and zinc. Related methods and membranes and batteries including the cross-linked polymeric material are also provided.Type: GrantFiled: June 19, 2017Date of Patent: February 9, 2021Assignee: CORNELL UNIVERSITYInventors: Lin Ma, Lynden Archer
-
Patent number: 10913810Abstract: A magnesium suppressant/flocculant for use in separating dolomite from calcium phosphate. The magnesium suppressant/flocculant may be applied at a mine site prior to subjecting ore fractions to phosphate flotation or at a chemical plant after grinding.Type: GrantFiled: May 8, 2019Date of Patent: February 9, 2021Assignee: ARR-MAZ PRODUCTS, L.P.Inventors: Lucas R. Moore, Todd Parker, Leon Willis
-
Patent number: 10913811Abstract: The present invention provides very finely divided polymer dispersions obtainable by at least one two-stage emulsion polymerization, wherein 1) an acid-rich first polymer P1 is prepared by a radical polymerization from a 1st composition comprising A) at least one monomer selected from the group of (cyclo)alkyl (meth)acrylates, vinylaromatics having up to 20 carbon atoms, a radically polymerizable compound selected from the group of ethylenically unsaturated nitriles having up to 20 carbon atoms, vinyl esters of carboxylic acids containing up to 20 carbon atoms, vinyl halides having up to 10 carbon atoms, and vinyl ethers of alcohols containing 1 to 10 carbon atoms B) at least one ?,?-ethylenically unsaturated carboxylic acid C) at least one crosslinking monomer with a keto or aldehyde group D) optionally at least one adhesion promoter E) optionally tert-butyl acrylate F) optionally further monomers M in the presence of a chain link transfer agent, 2) the polymer P1 prepared under 1) is admixed with a baseType: GrantFiled: March 14, 2017Date of Patent: February 9, 2021Inventors: Roelof Balk, Bastiaan Lohmeijer, Robert Wrazidlo
-
Patent number: 10913812Abstract: An alkoxy amine compound is provided, which has a chemical structure of: wherein each of R1 is independently H, C1-6 alkyl group, or C1-6 alkoxy group; R2 is C1-6 alkyl group, R3 is —(CxH2x)—OH or —(CxH2x+1), and x is 1 to 8; R4 is H or C1-6 alkyl group; R5 is and R6 is H or C1-8 alkyl group; R7 is H or C1-6 alkyl group, R8 is Ini is a residual group of a radical initiator; and n is an integer of 1 to 10000.Type: GrantFiled: January 30, 2019Date of Patent: February 9, 2021Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Meng-Wei Wang, Yu-Min Han, Chih-Hsiang Lin
-
Patent number: 10913813Abstract: A vinylamide block copolymer kinetic hydrate inhibitor and a preparation method thereof are disclosed. The vinylamide block copolymer kinetic hydrate inhibitor has a structural formula as shown in formula I. Through reverse atom transfer radical polymerization, under an anaerobic operating condition, with vinylcaprolactam and acrylamide as monomers, dimethylformamide as a solvent, azobisisobutyronitrile as an initiator, and a transition metal complex composed of a catalyst anhydrous copper chloride and a ligand 2,2?-bipyridine as a catalytic system, the method has achieved to catalyze a controllable free radical solution polymerization to obtain a poly(vinylcaprolactam-acrylamide) block copolymer kinetic hydrate inhibitor. The synthesized kinetic hydrate inhibitor has a controllable molecular weight, a narrow molecular weight distribution, and a controllable synthesis process, and exhibits an excellent inhibitory effect.Type: GrantFiled: May 31, 2018Date of Patent: February 9, 2021Assignee: GUANGZHOU INSTITUTE OF ENERGY CONVERSION, CHINESE ACADEMY OF SCIENCESInventors: Zhen Long, Qihang Ding, Deqing Liang
-
Patent number: 10913814Abstract: The present invention relates to an aqueous dispersion based on polyurethane-urea, a composition comprising the same, and a use of the same in a coating agent, a sealant and an adhesive. The aqueous polyurethane-urea dispersion comprises a polyurethane-urea dispersed therein having sulfonate and/or carboxylate groups and lateral carboxyl groups, wherein the amount of said sulfonate and or carboxylate groups is 1.5 to 15 mmol/100 g; said lateral carboxyl is introduced by an aminocarboxylic acid having an amino functionality of greater than 1; the amount of said lateral carboxyl is 1.5 to 9.5 mmol/100 g, based on the polyurethane-urea solid components. Compared with the prior art, the composition of the polyurethane-urea based aqueous dispersion and a carboxyl reactive cross-linking agent provided by the present invention has a good cross-linking property and an excellent heat-resistance, which is not prone to come unglued when being exposed to heat.Type: GrantFiled: December 27, 2016Date of Patent: February 9, 2021Assignee: Covestro Deutschland AGInventors: Chen Jin, Winnie Wei, Evgeny Avtomonov, Anand Khot, Yingdan Zhu
-
Patent number: 10913815Abstract: The present technology provides a curable resin composition that contains a urethane prepolymer having an isocyanate group, a coated amine formed by using a filler to coat solid amine having a melting point of 50° C. or higher, an isocyanate group-containing compound having an isocyanate group bonded to an aliphatic hydrocarbon group and having a hydrolyzable silyl group or (meth)acryloyl group, and a tertiary amine compound.Type: GrantFiled: November 5, 2015Date of Patent: February 9, 2021Inventors: Yuichi Matsuki, Megumi Abe
-
Patent number: 10913816Abstract: A one-component foam formulation contains a pre-polymer and a blowing agent, the pre-polymer being the reaction product of a polymeric polyol component having an average hydroxyl functionality in a range of 2.3 to 2.85 hydroxyl functionalities per molecule as determined using ASTM D4274-11 (method D); and where the polymeric polyol component has an effective average molecular weight in a range of 4500 and 10000 grams per mole, one or more than one type of chain extender molecule having 3 to 6 carbon atoms and 2 to 4 reactive functionalities selected from a group consisting of hydroxyl and amine functionalities per molecule, a polyisocyanate having a functionality in a range of 2.1 to 3.0 —NCO functionalities per molecule as determined by ASTM D7252-06(2011)e1; and a catalyst.Type: GrantFiled: September 20, 2016Date of Patent: February 9, 2021Assignee: DDP SPECIALTY ELECTRONIC MATERIALS US, LLCInventors: Beverly J. Selle, Deborah A. Schutter, Megan Thomas, Stéphane Costeux
-
Patent number: 10913817Abstract: The present invention relates to the use of bis-anhydrohexitol ethers as reactive diluents in a crosslinkable resin, adhesive, coating or composite matrix composition. Not only do these products make it possible to advantageously reduce the viscosity of the mixtures obtained, but they also lead to a very small reduction in the glass transition temperature of the crosslinked mixtures, compared to other reactive diluents, while spectacularly improving the mechanical properties of the latter such as the Young's modulus, the tensile strength, the elongation at break and the toughness.Type: GrantFiled: August 8, 2016Date of Patent: February 9, 2021Assignee: ROQUETTE FRERESInventors: Clothilde Buffe, Jean-Pierre Pascault, Loureiro Roi Meizoso, Pilar Prendes Gonzales, Senén Paz Abuin
-
Patent number: 10913818Abstract: The present invention relates to a tetramethylbiphenol epoxy resin represented by the following formula (1), which is an epoxy resin having excellent solvent solubility, a small hydrolyzable chlorine amount and further an appropriate melt viscosity and being effectively applicable, to a semiconductor sealing material and electrical or electronic components such as laminate sheet: wherein n represents an integer of 0 to 10.Type: GrantFiled: March 2, 2018Date of Patent: February 9, 2021Assignee: MITSUBISHI CHEMICAL CORPORATIONInventor: Kazumasa Oota
-
Patent number: 10913820Abstract: A process for producing a cationic dyeable polyester includes the steps of: (a) subjecting a combination of a bis-hydroxy alkyl terephthalate monomer of Formula (1) defined herein and an organic diacid monomer mixture which includes an aromatic dicarboxylic acid monomer and a sulfo group-containing aromatic dicarboxylic acid dyeable monomer to an esterification reaction to form an esterification reaction product; and (b) subjecting the esterification reaction product to a polycondensation reaction.Type: GrantFiled: January 16, 2019Date of Patent: February 9, 2021Assignee: Far Eastern New Century CorporationInventors: Der-Ren Hwang, Cheng-Ting Wang, Yen-Hsien Li
-
Patent number: 10913821Abstract: The present invention relates to a high molecular weight polymer having an aldaric acid as a constitutional unit, and a method for producing the same, and more specifically, relates to a thermoplastic polymer which comprises at least one repeating unit derived from an aldaric acid, and has a weight average molecular weight of 3,800 or more.Type: GrantFiled: March 29, 2017Date of Patent: February 9, 2021Assignees: ENSUIKO SUGAR REFINING CO., LTD., THE UNIVERSITY OF TOKYOInventors: Tadahisa Iwata, Yukiko Rogers, Yuxin Wu, Hisaharu Masaki, Tetsuya Ito, Koji Hara
-
Patent number: 10913822Abstract: The compound of the present application has a low melting point and excellent flexibility, and the like, so that a phthalonitrile resin or a prepolymer thereof or a polymerizable composition forming the same can exhibit excellent workability and a wide process window and it can be made to ensure improved impact strength. The compound can form the phthalonitrile resin or the like into a liquid phase or form it into a rubber phase. Such a phthalonitrile resin or the like can be applied to various applications.Type: GrantFiled: October 18, 2017Date of Patent: February 9, 2021Assignee: LG CHEM, LTD.Inventors: Sang Woo Kim, Seung Hee Lee, Ki Ho Ahn